Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button
arrow_left sharing button
arrow_right sharing button


WuXi Vaccines Named Best Contract Manufacturing Organization at ViE Awards 2024
Apr. 08, 2024
WuXi Vaccines Named Best Contract Manufacturing Organization at ViE Awards 2024


SHANGHAI, April 8, 2024 – WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), announced it was named “Best Contract Manufacturing Organization” at the 17th annual Vaccine Industry Excellence Awards (ViE) during the 2024 World Vaccine Congress.
The ViE Awards recognize outstanding achievements and innovations across the global vaccine industry, with award winners selected by a distinguished panel of industry experts, professionals, and key stakeholders within the vaccine community. The “Best Contract Manufacturing Organization Award” is presented to the organization that has demonstrated exceptional performance in various therapeutic areas, innovative service delivery methods, strong client relationships, high-quality outcomes, and sustained partnerships. WuXi Vaccines was particularly noted for its focus on global vaccine access, especially for low- and middle-income countries.
Mr. Jian Dong, CEO of WuXi Vaccines, commented, “We are deeply honored to be recognized with the ViE award for Best Contract Manufacturing Organization. This award is a reflection of WuXi Vaccines’ relentless pursuit of quality, reliability, and customer satisfaction. It reaffirms our commitment to advancing global health through cutting-edge vaccine development and manufacturing solutions.”
About WuXi Vaccines
WuXi Vaccines is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners’ vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., recombinant protein, viral, viral vectored, VLP, OMV, nucleic acid, conjugated vaccines). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (cell culture, viral, microbial, polysaccharide and protein conjugation), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can enable global clients to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health. For more information about WuXi Vaccines, please visit:


You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?